NEW YORK (AP) ¿ China-based baby formula maker Synutra International Inc. on Monday reported a fourth-quarter loss as sales slumped. Net loss for the quarter ended March 31 totaled $17.2 million, or 32 cents per share, compared with a profit of $19.3 million, or 36 cents per share, last year. Revenue fell 33 percent to $72.7 million from $108.2 million a year ago. In September, Synutra said a Chinese agency had found melamine in some of its products. It stopped buying milk from two regions in China that may have been the source of milk contaminated with the chemical melamine. Sales more than tripled on a sequential basis, however, and Synutra said it is making progress in regaining consumer confidence. For the fiscal year, loss totaled $100.6 million, or $1.86 per share, compared with net income of $45.7 million, or 85 cents per share, last year. Revenue fell 14 percent to $312.5 million. The company said the cost of the melamine contamination and associated recalls totaled $101.5 million for the year.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Technology
Pinterest's Earnings Report Doesn't Justify Pressing the Panic Button
The social media platform's guidance isn't that bad in light of its spending and growth strategy, and some of its first-quarter numbers were pretty solid.
Applied Materials' 2020 Outlook Provides Grounds for Cautious Optimism
Like other chip equipment makers, Applied is slogging through a rough 2019. But it outlined a case for better 2020 demand.
Nvidia Stops Issuing Full-Year Guidance: How Worried Should Investors Be?
The chipmaker posted a healthy quarter but now is declining to offer longer-term guidance to investors.
Defensive Investors Should Consider Procter & Gamble, Morgan Stanley Says
Plus, see why Nvidia's strong strong quarter may not be enough to make it a buy.